Delivery Order 36F79719D0217-36C26024F0421

Award Date 6/20/24
Potential Completion Date 6/19/25
Potential Value Not listed
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order is valued at $18,125.50 and provides the VA's Veterans Health Administration (VHA) with the oncology medication BALVERSA (erdafitinib) to support healthcare services for veterans. The delivery order is placed against Janssen Biotech's existing $3.1 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide BALVERSA (erdafitinib), an oncology medication, to the VA's Veterans Health Administration (VHA). The $15,090.62 delivery order was issued on an emergency basis to the pharmaceutical manufacturer under a $3.7 million Blanket Purchase Agreement (BPA) established in 2020, which allows VHA buying offices to efficiently...
The Department of Veterans Affairs (VA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows the VA's Veterans Health Administration (VHA) to procure prescription drugs for veteran healthcare programs. The order has a...
This is a firm fixed price delivery order awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The order is against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with a ceiling value of $17,642.95. The contract is for the chemotherapy drug BALVERSA 4 MG to support healthcare services for veterans. This delivery order is part of a larger $3.1 billion...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order, valued at $62,248.81, is for the cancer treatment drug BALVERSA to support healthcare services for veterans. The delivery order was issued under Janssen's General Services Administration Multiple Award Schedule Contract for Pharmaceuticals and Drugs (FSS-61-IB), which allows the VA to efficiently...
This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of the cancer treatment drug BALVERSA 4 MG. The award, with a ceiling value of $17,642.95, is a firm fixed price delivery order placed under a larger $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the Department of Veterans Affairs (VA). The contract has an ultimate completion date of September 13, 2024 and...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the pharmaceutical product BALVERSA 4MG TABS. The $17,642.95 order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract (FSS-61-IB) and has a completion date of June 30, 2024. Janssen Biotech Inc. is a for-profit manufacturer of specialty medications, including...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $15,754 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Janssen Biotech, Inc. for emergency supplies of Balversa (erdafitinib) 4 mg tablets. Performance will take place in Phoenix, Arizona with an anticipated completion date of August 17, 2022. The award utilizes the GSA Pharmaceuticals and Drugs schedule to procure this oncology...
This federal contract award is for BALVERSA (erdafitinib), an oncology medication, provided by Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.) to the Department of Veterans Affairs (VA). The $11,317.97 firm fixed price contract is a Blanket Purchase Agreement (BPA) call order under Janssen's $3.7 million single-award BPA established in August 2020, which allows VA buying offices to efficiently procure BALVERSA and other oncology drugs. Janssen also holds a $3.1 billion...

This is a firm fixed price delivery order issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the supply of the chemotherapy drug ERDAFITINIB (BALVERSA) 4MG TABLETS (56 TAB BTL). The order is placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, which is a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs for veteran healthcare programs. This particular delivery order has a potential value of $211,715.40 and a completion date of June 19, 2025. No set-aside designation was used for this contract award to the for-profit manufacturer Janssen Biotech Inc.

Generated 6/1/24, 10:07 AM